Eugene Cox
Overview
Explore the profile of Eugene Cox including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sethi V, Qin L, Cox E, Troconiz I, Della Pasqua O
Pain Ther
. 2024 Jan;
13(1):145-159.
PMID: 38183573
Introduction: Acetaminophen and topical diclofenac (AtopD) have complementary mechanisms of action and are therefore candidates for combination use in osteoarthritis (OA) pain. However, an evidence gap exists on their combination...
2.
Sethi V, Qin L, Troconiz I, Van der Laan L, Cox E, Della Pasqua O
Pain Ther
. 2024 Jan;
13(1):127-143.
PMID: 38183572
Introduction: The use of combination therapy of oral acetaminophen and topical diclofenac, having complementary mechanisms of action, is an attractive strategy to enhance the analgesic response in osteoarthritis (OA) pain....
3.
Qin L, Zhang N, Ishigami J, Miller 3rd E, Pfister M, Moran A, et al.
J Hum Hypertens
. 2021 Sep;
36(11):989-995.
PMID: 34556798
A model-based meta-analysis quantified comparative dyskalemia risk (hyper- or hypo-kalemia) in hypertensive patients treated with angiotensin receptor blockers (ARBs), a calcium channel blocker (CCB) and/or a thiazide diuretic (hydrochlorothiazide; HCTZ)...
4.
Dodds M, Xiong Y, Mouksassi S, Kirkpatrick C, Hui K, Doyle E, et al.
Br J Clin Pharmacol
. 2021 Feb;
87(9):3388-3397.
PMID: 33534138
During a pandemic caused by a novel pathogen (NP), drug repurposing offers the potential of a rapid treatment response via a repurposed drug (RD) while more targeted treatments are developed....
5.
Brown K, Comisar C, Witjes H, Maringwa J, de Greef R, Vishwanathan K, et al.
Br J Clin Pharmacol
. 2016 Dec;
83(6):1216-1226.
PMID: 28009438
Aims: To develop a population (pop) pharmacokinetic (PK) model for osimertinib (AZD9291) and its metabolite (AZ5104) and investigate the exposure-response relationships for selected efficacy and safety parameters. Methods: PK, safety...
6.
Namour F, Diderichsen P, Cox E, Vayssiere B, Van der Aa A, Tasset C, et al.
Clin Pharmacokinet
. 2015 Feb;
54(8):859-74.
PMID: 25681059
Background And Objectives: Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease. While less selective JAK...
7.
Maringwa J, Kagedal M, Wahlby Hamren U, Martin P, Cox E, Hamren B
J Clin Pharmacol
. 2014 Oct;
55(3):328-35.
PMID: 25280085
R788 (fostamatinib) is an oral prodrug that is rapidly converted into a relatively selective spleen tyrosine kinase (SYK) inhibitor R406, evaluated for the treatment of rheumatoid arthritis (RA). This analysis...
8.
Diderichsen P, Cox E, Martin S, Cleton A, Ribbing J
Clin Pharmacokinet
. 2013 Mar;
52(6):443-52.
PMID: 23494982
Background And Objectives: PF-00610355 is an orally inhaled long-acting β2-adrenoreceptor agonist that is being developed for the once-daily treatment of chronic obstructive pulmonary disease (COPD). The pharmacological effect is exerted...
9.
Diderichsen P, Cox E, Martin S, Cleton A, Ribbing J
Br J Clin Pharmacol
. 2013 Jan;
76(5):752-62.
PMID: 23323609
Aim: To assess the cardiovascular effects of a new inhaled long-acting β-adrenoceptor agonist PF-00610355 in COPD patients. Methods: Thirteen thousand and sixty-two heart rate measurements collected in 10 clinical studies...
10.
Girgis I, Nandy P, Nye J, Ford L, Mohanty S, Wang S, et al.
Epilepsia
. 2010 Oct;
51(10):1954-62.
PMID: 20880232
Purpose: To identify and validate the efficacious monotherapy dosing regimen for topiramate in children aged 2 to <10 years with newly diagnosed epilepsy using pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation bridging....